Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer

Published:2017-04 Issue:4 Volume:12 Page:633-643
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ding Pei Ni,Lord Sarah J.,Gebski Val,Links Matthew,Bray Victoria,Gralla Richard J.,Yang James Chih-Hsin,Lee Chee Khoon

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models;Li;Oncogene,2008

2. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker;Solca;J Pharmacol Exp Ther,2012

3. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy;Kim;Lung Cancer,2012

4. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L;Urata;J Clin Oncol,2016

5. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol,2016

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs);Drug Metabolism Reviews;2024-08-09

2. Adverse Effects of Gefitinib on Skin and Colon in a Lung Cancer Mouse Model;Recent Patents on Anti-Cancer Drug Discovery;2024-08

3. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis;Targeted Oncology;2024-06-01

4. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs;PharmacoEconomics - Open;2024-05-02

5. Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease;JTO Clinical and Research Reports;2024-04